These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 12808502)

  • 21. New targets for putative neuroprotective agents.
    Jantas-Skotniczna D; Kajta M; Lasoń W
    Acta Pol Pharm; 2006; 63(5):359-68. PubMed ID: 17357585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical potential of minocycline for neurodegenerative disorders.
    Blum D; Chtarto A; Tenenbaum L; Brotchi J; Levivier M
    Neurobiol Dis; 2004 Dec; 17(3):359-66. PubMed ID: 15571972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Is good old minocycline a new neuroprotective drug?].
    Melero-Fernández de Mera RM; García-Martínez E; Fernández-Gómez FJ; Hernández-Guijo JM; Aguirre N; Galindo MF; Jordán J
    Rev Neurol; 2008 Jul 1-15; 47(1):31-8. PubMed ID: 18592478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monocyte chemoattractant protein-1 and macrophage inflammatory protein-2 are involved in both excitotoxin-induced neurodegeneration and regeneration.
    Kalehua AN; Nagel JE; Whelchel LM; Gides JJ; Pyle RS; Smith RJ; Kusiak JW; Taub DD
    Exp Cell Res; 2004 Jul; 297(1):197-211. PubMed ID: 15194436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ubiquitin proteasome system as a pharmacological target in neurodegeneration.
    Hol EM; Fischer DF; Ovaa H; Scheper W
    Expert Rev Neurother; 2006 Sep; 6(9):1337-47. PubMed ID: 17009921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. To be or not to be (inflamed)--is that the question in anti-inflammatory drug therapy of neurodegenerative disorders?
    Marchetti B; Abbracchio MP
    Trends Pharmacol Sci; 2005 Oct; 26(10):517-25. PubMed ID: 16126283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imbalance of mononuclear cell infiltrates in the placental tissue from foetuses after spontaneous abortion versus therapeutic termination from 8th to 12th weeks of gestational age.
    Lambropoulou M; Tamiolakis D; Venizelos J; Liberis V; Galazios G; Tsikouras P; Karamanidis D; Petrakis G; Constantinidis T; Menegaki M; Papadopoulos N
    Clin Exp Med; 2006 Dec; 6(4):171-6. PubMed ID: 17191109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroprevention: a new challenge?
    Corvol JC
    Rev Neurol (Paris); 2012 Nov; 168(11):796-801. PubMed ID: 22902171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Will the revolutionary knowledge of apoptosis play an important role in medicine?].
    Løberg EM; Lømo J; Maehlen J
    Lakartidningen; 2000 Mar; 97(12):1389-93. PubMed ID: 10765620
    [No Abstract]   [Full Text] [Related]  

  • 30. [Development of preclinical diagnosis and preventive treatment of neurodegenerative diseases].
    Ugrumov MV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(11):4-14. PubMed ID: 26978045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apoptosis and human neurodegenerative diseases.
    Berry MD; Boulton AA
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Apr; 27(2):197-8. PubMed ID: 12657359
    [No Abstract]   [Full Text] [Related]  

  • 32. A brief review on current progress in neuroscience in China.
    Qiang M; Wu B; Liu Y
    Sci China Life Sci; 2011 Dec; 54(12):1156-9. PubMed ID: 22227910
    [No Abstract]   [Full Text] [Related]  

  • 33. [Child neurology and neuronal apoptosis: introductory remarks].
    Miyata Y; Takashima S
    No To Hattatsu; 1999 Mar; 31(2):120-1. PubMed ID: 10191632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Introducing a new volume of Neurodegenerative Disease Management.
    Dormer L
    Neurodegener Dis Manag; 2017 Feb; 7(1):1-4. PubMed ID: 28128039
    [No Abstract]   [Full Text] [Related]  

  • 35. Biochemical, cellular and behavioural aspects of neurodegeneration: the view from down under.
    Small DH
    Neurotox Res; 2005; 7(1-2):1-3. PubMed ID: 15639793
    [No Abstract]   [Full Text] [Related]  

  • 36. Hormones, autacoids, neurotransmitters and growth factors.
    Curr Opin Nephrol Hypertens; 1999 Jan; 8(1):105-33. PubMed ID: 9914867
    [No Abstract]   [Full Text] [Related]  

  • 37. Neurodegenerative Diseases: Implications of Environmental and Climatic Influences on Neurotransmitters and Neuronal Hormones Activities.
    Ayeni EA; Aldossary AM; Ayejoto DA; Gbadegesin LA; Alshehri AA; Alfassam HA; Afewerky HK; Almughem FA; Bello SM; Tawfik EA
    Int J Environ Res Public Health; 2022 Sep; 19(19):. PubMed ID: 36231792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bibliography. Current world literature. Hormones, autacoids, neurotransmitters and growth factors.
    Curr Opin Nephrol Hypertens; 2001 Jan; 10(1):117-39. PubMed ID: 11195044
    [No Abstract]   [Full Text] [Related]  

  • 39. [Pharmacological targets in neurodegenerative diseases].
    Segura T; Galindo MF; Rallo-Gutiérrez B; Ceña V; Jordán J
    Rev Neurol; 2003 Jun 1-15; 36(11):1047-57. PubMed ID: 12808502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.